Alain Prochiantz

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 6)

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 84(Granted Patents)

Company Filing History:

13 out of 5,089

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

patents

4. 3 out of 32

Ecole Normale Superieure

6. 1 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2022

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11357816 - Ligand controling interaction between gags with their effector molecules and use thereof (2022-06-14),

2. 10842852 - Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide (2020-11-24),

3. 10722554 - Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein (2020-07-28),

4. 10342851 - Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons (2019-07-09),

5. 10100307 - Use of a reverse-transcriptase inhibitor in the prevention and treatment of degenerative diseases (2018-10-16),

6. 9950033 - Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons (2018-04-24),

7. 9868783 - Inhibition of the synthesis of beta-app or the activity of the A-β peptide in the choroid plexus (2018-01-16),

8. 8575105 - Use of the engrailed homeodomain protein as anxiolytic (2013-11-05),

9. 8242088 - Carrier vectors through an epithelium with tight junctions (2012-08-14),

10. 7115380 - Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (APP) (2006-10-03),

11. 6905832 - Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP) (2005-06-14),

12. 6656735 - Method for identification of target genes of transcription factors (2003-12-02),

13. 6080724 - Peptides which can be used as vectors for the intracellular addressing (2000-06-27),

14. 5888762 - Neurotropic growth factors comprising a homeobox peptide (1999-03-30),

Title: The Innovations of Alain Prochiantz: A Pioneer in Neurogenesis

Introduction

Alain Prochiantz, a distinguished inventor based in Paris, France, has made significant contributions to the field of neuroscience and biochemistry. With a remarkable portfolio of 14 patents, Prochiantz's work focuses on innovative compounds and methods that advance our understanding of neurogenesis and related pathologies.

Latest Patents

Among his notable inventions, Alain Prochiantz has developed the patent titled "Ligand controlling interaction between GAGs with their effector molecules and use thereof." This invention pertains to new compounds that mimic glycosaminoglycans, effectively controlling their interactions with effector molecules. These peptide compounds hold promise as therapeutic agents aimed at stimulating neurogenesis and treating various nervous system-related disorders.

Another groundbreaking patent involves "Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide." This invention outlines a method for delivering polypeptides to Otx2 target cells by utilizing a chimeric polypeptide containing a specific targeting peptide. Such methodologies highlight Prochiantz's innovative approach to cellular biology and therapeutic delivery systems.

Career Highlights

Alain Prochiantz's career is marked by significant positions at esteemed research institutions, including the Centre National de la Recherche Scientifique and the Collège de France. His tenure at these organizations has solidified his reputation as a leading figure in the field of scientific research, particularly in neurobiology.

Collaborations

Throughout his career, Prochiantz has collaborated with esteemed colleagues such as Kenneth Lee Moya and Rajiv Joshi. These partnerships reflect his dedication to advancing scientific knowledge and fostering innovation within the research community.

Conclusion

Alain Prochiantz stands out as a notable inventor whose research is at the forefront of understanding neurogenesis. His extensive patent portfolio underscores his commitment to developing innovative solutions for treating nervous system disorders. As neuroscience continues to evolve, Prochiantz's contributions will undoubtedly play a pivotal role in the future of medical research and therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.